Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

Compared with whole brain radiation, stereotactic radiation reduces the rates of neurologic deaths in patients with SCLC and ...

Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial ( NCT05785611; Eudra CT 2022-501354-10-01 ), i evaluating filgotinib (marketed as Jyseleca ® in ...

Alfasigma announces positive results from OLINGUITO phase 3 trial of filgotinib to treat adult patients with active axial spondyloarthritis: Bologna Wednesday, July 30, 2025, 18:0 ...

Background There are conflicting results in the literature regarding the association between radiographic knee osteoarthritis (OA) and symptoms and function in subjects with previous anterior cruciate ...

Radiographic recall has been advised annually for up to four years after RCT based on expected healing time, a time during which the healing curve flattens out. 4, 5 Guidelines have previously ...

Alfasigma has announced positive topline results from its OLINGUITO phase 3 trial evaluating filgotinib in adults with active ...

Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials assessing new therapies in mHSPC with ...

Given the limited awareness of non-radiographic axial spondyloarthritis, differentiating this disease from radiographic disease and prescribing appropriate therapy remains a key challenge ...

A 2013 narrative literature review concluded that the prevalence of radiographic PF OA in individuals’ post-ACL and/or meniscus ruptures was approximately 50%. 6 A recent systematic review described ...